Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Pabst

Showing results (101-110 of 332) with videos related to

Pageof 34
Sort By:
International Journal of Molecular Sciences|May 13, 2026
Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab OzogamicinSophie Helfenstein, Inna Shaforostova, Katja Seipel, et al.
ACS Pharmacology & Translational Science|December 21, 2020
RNA Targeting in Acute Myeloid LeukemiaAlessandra Messikommer, Katja Seipel, Stephen Byrne, et al.
Blood|April 8, 2011
Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AMLSimon Haefliger, Christiane Klebig, Kerstin Schaubitzer, et al.
Journal of Clinical Medicine|September 23, 2022
Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation-A Phase I StudyChristian Rausch, Ulrike Bacher, Manuela Rabaglio, et al.
Cancers|February 25, 2022
Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AMLEkaterina Gurevich, Michael Hayoz, Yolanda Aebi, et al.
Cancers|April 13, 2023
Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell LymphomaFabrizio Huwyler, Rebekka Kunz, Ulrike Bacher, et al.
Hematological Oncology|October 21, 2025
Randomized Phase II Study of Brentuximab-Vedotin With High-Dose Chemotherapy in CD30 Positive LymphomaChristian Rausch, Ulrike Bacher, Manuela Rabaglio, et al.
Leukemia & Lymphoma|October 14, 2016
Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML)Chantal Fridle, Michael Medinger, Matthias C Wilk, et al.
Leukemia Research|June 26, 2012
The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potentialIsabelle von Grünigen, Joëlle Raschle, Ilka Rüsges-Wolter, et al.
Blood Reviews|May 6, 2018
Current status and trends in the diagnostics of AML and MDSEvgenii Shumilov, Johanna Flach, Alexander Kohlmann, et al.
Pageof 34

Showing results (101-110 of 332) with videos related to

Sort By:
Pageof 34
International Journal of Molecular Sciences|May 13, 2026
Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab OzogamicinSophie Helfenstein, Inna Shaforostova, Katja Seipel, et al.
ACS Pharmacology & Translational Science|December 21, 2020
RNA Targeting in Acute Myeloid LeukemiaAlessandra Messikommer, Katja Seipel, Stephen Byrne, et al.
Blood|April 8, 2011
Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AMLSimon Haefliger, Christiane Klebig, Kerstin Schaubitzer, et al.
Journal of Clinical Medicine|September 23, 2022
Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation-A Phase I StudyChristian Rausch, Ulrike Bacher, Manuela Rabaglio, et al.
Cancers|February 25, 2022
Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AMLEkaterina Gurevich, Michael Hayoz, Yolanda Aebi, et al.
Cancers|April 13, 2023
Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell LymphomaFabrizio Huwyler, Rebekka Kunz, Ulrike Bacher, et al.
Hematological Oncology|October 21, 2025
Randomized Phase II Study of Brentuximab-Vedotin With High-Dose Chemotherapy in CD30 Positive LymphomaChristian Rausch, Ulrike Bacher, Manuela Rabaglio, et al.
Leukemia & Lymphoma|October 14, 2016
Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML)Chantal Fridle, Michael Medinger, Matthias C Wilk, et al.
Leukemia Research|June 26, 2012
The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potentialIsabelle von Grünigen, Joëlle Raschle, Ilka Rüsges-Wolter, et al.
Blood Reviews|May 6, 2018
Current status and trends in the diagnostics of AML and MDSEvgenii Shumilov, Johanna Flach, Alexander Kohlmann, et al.
Pageof 34